Novartis Can't Halt Janssen's Promo Comparing Their Psoriasis Drugs
Executive Summary
US judge is 'troubled' by Janssen's omission of relevant safety data in summary of Tremfya v. Cosentyx study, but finds Novartis claim of irreparable harm is 'too speculative.'
You may also be interested in...
Comparative Claims: CFL Guidance Gives Opening; OPDP Research May Close It
US FDA’s 'consistent with labeling' guidance prompts more sponsors to consider comparative promotional claims, but any minimization of product safety issues still runs the risk of enforcement, legal experts say; Office of Prescription Drug Promotion’s research agenda on consumer understanding of Rx ad claims could result in an attempt to limit comparative claims.
Novartis Settles Short-Lived Suit Over Janssen's Psoriasis Drug Promo
The companies resolve litigation as competition in the psoriasis drug market intensifies; there are now 12 approved products in the US, with TNF-alpha inhibitors still dominating.
Novartis Settles Short-Lived Suit Over Janssen's Psoriasis Drug Promo
Companies resolve litigation as competition in the psoriasis drug market intensifies; there are now 12 approved products in the US, with TNF-alpha inhibitors still dominating.